We are pleased to share that Amarna Therapeutics has received positive feedback from the FDA. For more information:
We are excited to share that we received positive and encouraging feedback during the INTERACT meeting with the FDA on July 31, 2024. This meeting focused on the development of AM510, our gene therapy for Type 1 diabetes. 🎉 We would like to thank the FDA on their invaluable insights on our clinical trial design, safety assessments, and the overall development program. We are pleased and confident that the guidance provided will significantly enhance our approach, ensuring the safety and efficacy of AM510 for patients who rely on insulin therapy. 💡 In light of this, we have issued a press release detailing the productive discussions and the steps we are taking to advance this innovative treatment. We look forward to continuing our interactions with the FDA and other health authorities as we work relentlessly towards our vision to cure Type 1 Diabetes. 🚀 Read the news here: https://lnkd.in/eztzVB6P https://lnkd.in/e6U_b5U3 Stay tuned for more updates! #AmarnaTherapeutics #GeneTherapy #Type1Diabetes #FDA #Innovation #Healthcare #FDAINTERACT